Cyclerion Therapeutics
TOP TEN
Cyclerion Therapeutics
CEO : Peter Hecht
With its team of determined experts to develop innovative medicines , Cyclerion Therapeutics is a clinicalstage biopharmaceutical company , focused on “ unlocking the full therapeutic potential of the NO-cGMP pathway ,” addressing the broad range of serious central nervous system ( CNS ) diseases .
At the forefront of CNS drug development , Cyclerion Therapeutics ’ systems biology approach combines genetic and proteomic data to identify CNS diseases . Its approach identifies dysfunctional NO-sGC-cGMP signaling
as the common pathophysiologic thread for both neurodegenerative diseases and neuropsychiatric diseases .
“ In diseases associated with deficits in the NO-sGC-cGMP pathway , CY6463 [ a sGC stimulator ] has the potential to address the underlying pathophysiology by restoring appropriate endogenous signaling and maintaining the precise spatial and temporal control that is the hallmark of this signaling pathway ,” says Cyclerion Therapeutics .
technologymagazine . com 159